A multicentre, phase III, open-label, randomized study in patients with advanced follicular lymphoma evaluating the benefit of maintenance therapy with rituximab (Mabthéra® ) after induction of response with chemotherapy plus rituximab in comparison with no maintenance therapy.

Trial Profile

A multicentre, phase III, open-label, randomized study in patients with advanced follicular lymphoma evaluating the benefit of maintenance therapy with rituximab (Mabthéra® ) after induction of response with chemotherapy plus rituximab in comparison with no maintenance therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Feb 2018

At a glance

  • Drugs Rituximab (Primary) ; Chlorambucil; Cyclophosphamide; Doxorubicin; Fludarabine; Mitoxantrone; Prednisolone; Vincristine
  • Indications Follicular lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms PRIMA
  • Most Recent Events

    • 20 Feb 2018 Results of gene-expression profiling score for prediction of outcome in patients with follicular lymphoma, published in the Lancet Oncology
    • 12 Dec 2017 Results of long term follow up, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 09 Mar 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top